Skip to main content

Table 1 Baseline patient characteristics

From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Patient characteristics

Patients (n = 65)

Median age, years (range)

51 (18–84)

Age group, n (%)

  < 60 years

48 (73.8)

  ≥ 60 years

17 (26.2)

Sex, n (%)

 Male

34 (52.3)

 Female

31 (47.7)

Disease, n (%)

 AML

33 (50.8)

  De novo AML

23 (35.4)

  Secondary AMLa

10 (15.4)

 ALL

31 (47.7)

  Philadelphia-positive

3 (4.6)

  Philadelphia-negative

28 (43.1)

 ABL

1 (1.5)

Risk group, n (%) [1, 36]

 Favorable

3 (4.6)

 Intermediate

29 (44.6)

 Poor

30 (46.2)

 Unknown

3 (4.6)

Risk group (AML only), n (%) [1]

 Favorable

3 (9.1)

 Intermediate

16 (48.5)

 Poor

12 (36.4)

 Unknown

2 (6.0)

Induction chemotherapy, n (%)

 AID-based regimen

30 (46.2)

 Modified FLAI

3 (4.6)

 VPD-based regimen

30 (46.2)

 ADVP-based regimen

2 (3.1)

Median BM blast percentage at diagnosis (range)

80.0 (12.9–98.5)

Median duration of micafungin treatment, days (range)

24 (1–68)

Median time from induction chemotherapy to severe neutropenia (ANC < 500/μL), days (range)

24 (11–84)

  1. Abbreviations: AML Acute myeloid leukemia, ALL Acute lymphoblastic leukemia, ABL Acute biphenotypic leukemia, AID Cytarabine + idarubicin, FLAI Fludarabine + cytarabine + idarubicin, VPD Vincristine + prednisolone + daunorubicin, ADVP Cytarabine + daunorubicin + vincristine + prednisolone, BM Bone marrow, ANC Absolute neutrophil count; aSecondary AML (10) included AML transformation from myelodysplastic syndrome (8), AML transformation from chronic myelomonocytic leukemia (1) and treatment-related AML (1)